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Cancer cachexia is a devastating metabolic syndrome characterized by systemic inflamma-
tion and massive muscle and adipose tissue wasting. Although it is responsible for
approximately one-third of cancer deaths, no effective therapies are available and
the underlying mechanisms have not been fully elucidated. We previously identified the
bromodomain and extra-terminal domain (BET) protein BRD4 as an epigenetic regulator
of muscle mass. Here we show that the pan-BET inhibitor (+)-JQ1 protects tumor-bearing
mice from body weight loss and muscle and adipose tissue wasting. Remarkably, in
C26-tumor-bearing mice (+)-JQ1 administration dramatically prolongs survival, without
directly affecting tumor growth. By ChIP-seq and ChIP analyses, we unveil that BET proteins
directly promote the muscle atrophy program during cachexia. In addition, BET proteins are
required to coordinate an IL6-dependent AMPK nuclear signaling pathway converging on
FoxO3 transcription factor. Overall, these findings indicate that BET proteins may represent a
promising therapeutic target in the management of cancer cachexia.
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Cancer cachexia is a multifactorial metabolic syndromecharacterized by systemic inflammation and muscle andadipose tissue wasting, which lead to weight loss despite
adequate nutritional support1.
It accompanies majority of cancer patients with advanced
disease, and has a stronger prevalence at earlier cancer stages in
solid tumors, such as gastric, pancreatic, lung, colorectal, and
head and neck2. Cachexia is predictive of reduced response to
tumor therapies and is associated with increased risk of compli-
cations that correlate with fatal outcome1,2.
Though cachexia accounts for nearly 30% deaths of
cancer patients3,4, no effective treatment is currently available.
It was recently reported that pharmacological intervention
aimed at blocking muscle wasting effectively prolongs survival
in experimental models of cancer cachexia5,6. In humans,
therapeutic intervention with a single agent targeting exclusively
systemic inflammation, low food intake, or catabolic pathways
regulating muscle mass has proven ineffective to counteract
cachexia1,7. A combinatorial approach is advocated for successful
management of cachexia, in order to concurrently address
different facets of the syndrome, such as inflammation and
muscle atrophy8. IL6, the ubiquitin proteasome system, and
autophagy have been individually investigated for potential
therapeutic intervention, with limited success9–12. Thus, the
precise elucidation of molecular pathways underlying cancer
cachexia is crucial for the identification of novel key targets,
which regulate multiple pathophysiological aspects of the disease
and that become appealing for therapeutic intervention. Tran-
scription factors and epigenetic regulators are of
particular interest in this scenario, as they hold the potential
to reprogram multiple transcription programs in different
tissues and orchestrate coordinated transcription in different
districts1,7,12.
The onset of cachexia is thought to depend both on tumor-
secreted factors and on the host response. In skeletal muscle and
adipose tissues, cytokines and other factors (i.e., tumor necrosis
factor alpha (TNFα), interleukin 6 (IL6), interleukin 1 beta
(IL1β), myostatin, activin, parathyroid hormone-related protein
(PTHrP)) derived by the tumor, the host immune system,
or mesenchymal tissues trigger an intracellular signaling cascade,
which translates into transcriptional changes in the gene-
expression programs, eliciting catabolic responses1. In cachexia-
induced muscle atrophy, two main catabolic pathways are
activated: the ubiquitin-proteasome degradation system, through
transcriptional upregulation of MAFbx/Atrogin-1 and MuRF1
ubiquitin-ligases, and autophagy13–15. The transcription factor
FoxO3 orchestrates the expression of key factors of both catabolic
pathways, in several muscle wasting conditions16. Although co-
activators and chromatin regulators likely take part in the tran-
scriptional modulation of catabolic genes, the epigenetic
mechanisms underlying their activation in cachexia are poorly
elucidated.
We recently reported that, in an in vitro model of
glucocorticoid-induced skeletal muscle atrophy, the bromodo-
main protein BRD4 plays a role in controlling myotubes size.
Accordingly, BRD4 blockade with the bromodomain and extra-
terminal domain (BET) proteins inhibitor (+)-JQ1 prevents
atrophy of dexamethasone-treated myotubes17. Taking into
account these findings and the compelling number of reports
highlighting the ability of BET inhibitors to challenge progression
of several forms of cancer18–21 and the promising prospect of
developing (+)-JQ1 derivatives in the clinic22, we asked whether
BET proteins are involved in the transcriptional activation of
catabolic genes in cancer cachexia, and whether the BET small
inhibitor (+)-JQ1 may have a beneficial effect by preventing
muscle wasting.
We report that BRD4 directly associates with regulatory
regions of key catabolic genes in skeletal muscle and that BRD4
recruitment dramatically increases during muscle wasting. BRD4
blockade by (+)-JQ1 administration results in BRD4 loss from
catabolic genes loci and muscle sparing.
In addition, BETs blockade reduces systemic IL6 and PTHrP
levels, and adipose tissue loss.
Importantly, BRD2 also participates to the regulation of a
subset of catabolic genes in skeletal muscle and to the tran-
scriptional modulation of IL6 and PTHrP. IL6 reduction prevents
AMPK activation in muscles of cachectic mice. Notably, we
describe that during cancer cachexia AMPK directly regulates
transcription of catabolic genes, by occupying their promoter
regions. Additionally, accumulation of the active form of AMPK
in the nuclear compartment of cachectic myofibers contributes to
FoxO3 phosphorylation, which promotes transcriptional activa-
tion. Overall, BET blockade by (+)-JQ1 administration orches-
trates a dual control on the expression of genes involved in
muscle atrophy, by impairing BRD4 and BRD2 direct occupancy
at catabolic genes and by restraining the IL-6/AMPK/FoxO3 axis
activation. Thus, BET blockade in skeletal muscle and tumor
ameliorate skeletal muscle integrity in C26-tumor-bearing mice.
Results
C26 adenocarcinoma cells growth is resistant to JQ1. To
explore the involvement of the BET inhibitor (+)-JQ1 in the
activation of catabolic genes and muscle wasting in cancer
cachexia, we first established (+)-JQ1 sensitivity in nine cell lines
commonly employed in experimental models of cancer cachexia,
by assessment of (+)-JQ1 impact on viability after 72 h of (+)-JQ1
treatment, at three different doses (0.1, 0.5, and 1 μM). Eight of
the nine cell lines displayed sensitivity to (+)-JQ1 for viability,
while C26 colon adenocarcinoma cells were only mildly affected
by the treatment, at the three concentrations (Fig. 1a). In agree-
ment with (+)-JQ1’s well-described antineoplastic function, we
observed a significant decrease (p< 0.0001, unpaired t-test) in
tumor weight when mice were inoculated with melanoma B16
tumors and treated with (+)-JQ1 (20 mg/kg/day) for 10 days
before sacrifice (Fig. 1b). Because of C26 colon carcinoma cells
resistance to (+)-JQ1 treatment in vitro, C26 xenografts were
selected as a suitable model to in vivo investigate the effect of
(+)-JQ1 administration on cancer cachexia. To challenge BET
protein function, tumor-bearing mice were treated with the BET
inhibitor (+)-JQ1 or its inactive enantiomer (−)-JQ1 at two doses
(20 and 50 mg/kg) daily, starting the day following tumor cells
inoculation, for 12 days. Notably, tumor weight was not affected
by (+)-JQ1 administration in this experimental model (Fig. 1c).
In addition, (+)-JQ1 administration did not impact c-Myc protein
levels21, Caspase-3 activation23 (Fig. 1d) phosphorylated histone
H324 (Supplementary Fig. 1), suggesting that C26 adenocarci-
noma cells proliferation and apoptosis were not influenced by
(+)-JQ1 administration.
JQ1 prevents muscle loss and prolongs survival in cachexia.
Tumor-bearing animals treated with either the vehicle or the
inactive enantiomer (−)-JQ1 (20 and 50 mg/kg/day) lost body
weight starting 10 days after C26 cells inoculation, and reached
22% of total body weight at day 12. In contrast, body weight was
comparable in (+)-JQ1-treated mice and control animals
throughout the treatment and at the day sacrifice, suggesting that
(+)-JQ1 administration prevented wasting, at both doses (20 and
50 mg/kg/day) (Fig. 2a). Likewise, starting from day 9, food intake
was dramatically reduced in C26-bearing mice treated with
vehicle or (−)-JQ1, but not in the case of (+)-JQ1-treated tumor-
bearing mice and control animals until the day of sacrifice
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(Fig. 2b). Importantly, even at the lowest dose (20 mg/kg/day),
(+)-JQ1 treatment was associated with a significantly (p= 0.0004,
log-rank (Mantel–Cox) test) prolonged survival compared to
vehicle-treated animals, with a shift of the median survival from
16 to 28 days (Fig. 2c). To provide a more therapeutically relevant
preclinical model, we started (+)-JQ1 administration at a mod-
erate cachexia stage, when C26-tumor-bearing mice displayed an
average 10% of weight loss. Surprisingly, (+)-JQ1 treatment was
able to significantly prolong survival (p= 0.0005, log-rank
(Mantel–Cox) test) and partially reverse cachexia, shifting med-
ian survival from 16 to 28 days (Fig. 2c).
When JQ1 was administered the day after tumor cell
inoculation, cachexia was delayed and C26-tumor-bearing mice
started to lose weight at day 24 (Supplementary Fig. 2, gray line).
Furthermore, when treatment was started during moderate
cachexia, C26-tumor-bearing mice partially reversed weight loss
few days after (+)-JQ1 treatment started, and their weight was
stabilized till day 23, further delaying cachexia (Supplementary
Fig. 2, blue line).
To further evaluate body sparing of (+)-JQ1-treated
animals, we analyzed body composition. (+)-JQ1 treatment
fully prevented tibialis anterior (TA), extensor digitorum
longus (EDL), soleus, and epididymal fat mass loss observed in
vehicle and (−)-JQ1-treated C26-tumor-bearing animals
(Fig. 2d–g). Consistently with metabolic alterations observed
in cancer cachexia25,26, C26-tumor implantation determined
a strong increase in plasma LDL cholesterol, which was
hindered by (+)-JQ1 administration (Supplementary Fig. 3b).
No differences were detected in both total cholesterol and HDL
cholesterol among the six experimental groups (Supplementary
Fig. 3a, c). Other organs, such as heart were unaffected by (+)-JQ1
treatment (Supplementary Fig. 3d); testis was used as a positive
control for (+)-JQ1 efficacy since testis mass was reported to
be sensitive to (+)-JQ1 treatment27 (Supplementary Fig. 3e).
Morphological analysis of the TA confirmed that (+)-JQ1
administration counteracted the reduction in myofiber size
observed in vehicle-treated C26-tumor-bearing mice (Fig. 2h;
Supplementary Fig. 4a, b). One of the main hallmarks of cancer-
associated cachexia, such as impairments in physical activity, was
prevented upon (+)-JQ1 administration and (+)-JQ1-treated
animals performed significantly (p= 0.0003, one-way ANOVA)
better in the treadmill test, when compared to cachectic vehicle-
treated animals (Fig. 2i). We conclude that (+)-JQ1 administra-
tion to C26-tumor-bearing mice prevents muscle and fat tissue
loss and blocks cachexia progression. The outcome is a prolonged
survival through a mechanism unrelated to tumor growth.
JQ1 prevents catabolic pathways activation in muscle. During
cancer cachexia two major degradative pathways mediate skeletal
muscle loss: the ubiquitin/proteasome system (UPS) and the
autophagy pathway13,15. As expected, fast and slow myosin heavy
chain proteins were dramatically reduced both in vehicle and
(−)-JQ1-treated mice, 12 days after tumor implantation.
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Fig. 1 Response to JQ1 in cancer cell lines used to study cancer cachexia. a Viability rates of JQ1-treated cells, calculated by measuring the viable cell
number after 72 h in culture. Results are normalized to the proliferation of vehicle/DMSO-treated cells, set to 100% (n= 3). Statistical analysis was
performed by using one-way ANOVA followed by Tukey’s post hoc test. Data represent means± SD. *p< 0.05; **p< 0.01; ***p< 0.001 vs. DMSO.
b Ten days after B16-tumor cells inoculation, mice were treated either with vehicle or (+)-JQ1 (20mg/kg/day) for 10 days. Tumor weight after necropsy is
shown. Animals per group: n= 7. Data represent means± SD. Statistical analysis was performed by using Student’s unpaired t-test. ***p< 0.001 indicates
statistical significance vs. B16 + veh. c Tumor weight at the day of sacrifice (day 12) in C26-tumor-bearing mice (animals per group: n= 10). Data represent
means± SD. Statistical analysis was performed by using one-way ANOVA followed by Tukey’s post hoc test. d c-Myc and cleaved-Caspase-3 levels were
quantified by immunoblots using tumor whole extracts (animals per group: n= 4)
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Conversely, TA from (+)-JQ1-treated animals displayed fast and
slow myosin levels comparable to control animals (Fig. 3a; Sup-
plementary Fig. 5a). Accordingly, in vitro degradation assays
showed that fast myosin degradation was sustained in vehicle and
(−)-JQ1-treated muscle extracts, but was abrogated in muscle
extracts from (+)-JQ1-treated C26-tumor-bearing mice (Fig. 3b).
(+)-JQ1 administration prevented transcriptional activation of
ubiquitin-ligases responsible for skeletal muscle protein degra-
dation, MuRF1 (p< 0.0001, one-way ANOVA), MAFbx/Atrogin1
(p< 0.0001, one-way ANOVA), and Fbxo30/Musa1 (p= 0.0001,
one-way ANOVA), which were significantly increased in vehicle
and (−)-JQ1-treated tumor-bearing mice compared to the control
animal group (Fig. 3c, d; Supplementary Fig. 5b). MAFbx/Atro-
gin1 protein levels were maintained at basal levels in
muscles from (+)-JQ1-treated C26-tumor-bearing mice, although
they were significantly upregulated (p< 0.0001, one-way
ANOVA) in vehicle and (−)-JQ1-treated cachectic mice
(Fig. 3e). Autophagy undergoes both short- and long-term acti-
vation during cachexia9,15,28; accordingly autophagy-related
transcripts Bnip3, LC3b, GABARAPL1, Atg7, and CathepsinL
were considerably increased in vehicle and (−)-JQ1-treated C26-
tumor-bearing mice. (+)-JQ1 treatment hindered the transcrip-
tional upregulation of autophagy-related genes (Fig. 3f–h; Sup-
plementary Fig. 5c, d), and hampered the conversion of LC3 from
the unlipidated (LC3-I) to the lipidated form (LC3-II) (Fig. 3i).
AMPK-dependent activatory phosphorylations of Ulk1 and
Beclin1, which are involved in autophagy initiation, were
increased in vehicle and (−)-JQ1-treated tumor-bearing mice, but
not in the (+)-JQ1-treated animals (Fig. 3j; Supplementary
Fig. 5e). Taken together, these results reveal that (+)-JQ1 treat-
ment prevents UPS and autophagy induction in TA muscles of
C26-tumor-bearing mice.
JQ1 prevents BETs occupancy at catabolic genes in cachexia.
To understand the role of BRD4 in transcriptional regulation
of tumor-induced skeletal muscle wasting, we mapped the
genome-wide distribution of BRD4 in skeletal muscles from
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Fig. 2 JQ1 prolongs survival, and prevents muscle and white fat wasting. a Body weight chart of control, vehicle, (−)-JQ1, and (+)-JQ1-treated C26-tumor-
bearing mice. Day 0: tumor implantation. Day 1: JQ1 treatment started. Age-matched normal control mice were treated with vehicle (animals per group:
n= 10). Data represent means± SD. Statistical significance refers to (+)-JQ1-treated animals vs. vehicle and (−)-JQ1-treated animals. b Chart displaying food
intake in the six animal groups described in a. Data represent means± SD. Statistical significance refers to (+)-JQ1-treated animals vs. vehicle and (−)-JQ1-
treated animals. c Survival rate of C26-tumor-bearing mice was measured in two animal groups: vehicle (veh) and (+)-JQ1 20mg/kg/day. Treatment was
started either at day 1 (gray line) or when the average weight loss was 10% (blue line) (animals per group: n= 7). d Epididymal adipose tissue was weighted
at day of sacrifice (day 12) in the six animal groups (animals per group: n= 10). Data represent means± SD. e–g TA, EDL, and soleus were weighted 12 days
after C26 cell implantation (animals per group: n= 10). Data represent means± SD. h TA muscle morphology of Ctrl and C26-tumor-bearing mice treated
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performed by using one-way ANOVA followed by Tukey’s post hoc test in a, b, d–g, and i log-rank (Mantel–Cox) test in c
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control and C26-tumor-bearing mice treated with either (−)-JQ1
(20 mg/kg/day) or (+)-JQ1 (20 mg/kg/day) by ChIP-seq. ChIP-
seq data were analyzed using MACS peak calling tool29 at the
FDR level of 5% (q-value= 0.05). Genes were assigned using a
proximity distance of 50 kb from gene body. Correlation analysis
of BRD4 peaks in cachexia/control and cachexia/cachexia (+)-JQ1
treatment revealed that many regions gaining BRD4 during
cachexia have reduced BRD4 upon (+)-JQ1 treatment (Fig. 4a). In
control skeletal muscle, BRD4 peaks were assigned to 11,581
genes and localized in intergenic (37%), intronic regions (35%),
5′/3′UTR (20%), and exons (7%). BRD4 enrichment was evident
in 492 assigned genes in skeletal muscle from C26-tumor-bearing
mice. Acquired BRD4 peaks lay primarily in intronic regions
(59%), suggesting that they may represent regulatory regions
(Fig. 4b). Gene Ontology analysis of biological processes on genes
displaying increased BRD4 recruitment in cachexia revealed
enrichment in categories related to inflammatory pathways and
catabolic processes, key events occurring in skeletal muscle during
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Fig. 3 Muscle proteolysis and autophagy are hindered by JQ1 administration. a Representative immunoblot showing fast myosin heavy chain (MyHC)
protein expression in TA whole extracts from the six animal groups. Upper panel shows quantification of immunoblot bands from four animals per group.
Data represent means± SD. b TA extracts from control and C26-tumor-bearing mice (animals per group: n= 3) were used in an in vitro degradation assay
to reveal fast MyHC degradation in control vs. tumor-bearing mice treated with vehicle or JQ1 (−/+). c, d Total RNA was extracted from TA muscles from
control and C26-tumor-bearing mice (animals per group: n= 10) treated with vehicle or JQ1 (−/+) and expression levels of MuRF1, MAFbx/Atrogin-1 were
measured by quantitative RT-PCR. Data represent means± SD. e Representative western blot of MAFbx/Atrogin-1 on TA whole extracts (animals per
group: n= 4). Bands quantifications are shown in the upper panel. Data represent means± SD. f–h Quantitative RT-PCR of autophagy genes (Bnip3,
GABARAPL1, Cathepsin L) from control and C26-tumor-bearing mice. Ten animals were used for each experimental group. Data represent means± SD.
i, j Representative western blot for LC3 and p-Ulk1 in TA extracts of control and C26-tumor-bearing mice (animals per group: n= 4). Upper panel:
quantification of normalized band intensity. Data represent means± SD. Statistical analysis was performed by using one-way ANOVA followed by Tukey’s
post hoc test. *p< 0.05; **p< 0.01; ***p< 0.001. “a” indicates statistical significance compared to control; “b” indicates statistical significance compared to
C26 + vehicle; “c” indicates statistical significance compared to C26 + (−)-JQ1 20mg/kg/day; “d” indicates statistical significance compared to C26 +
(−)-JQ1 50mg/kg/day
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cancer cachexia (Fig. 4c; Supplementary Data 1). BRD4 occu-
pancy was higher in 136 assigned genes in skeletal muscles from
cachectic mice, when compared to muscles from (+)-JQ1-treated
animals. Notably, these genes were enriched in several categories
related to catabolism and inflammation, suggesting that JQ1
treatment reduced BRD4 engagement in pro-cachectic genes
(Fig. 4c; Supplementary Data 1).
In atrophying muscles, BRD4 was increased at known
regulatory regions and in the gene bodies of key atrophy-
related genes (Fbxo32 and Trim63) encoding for the muscle-
specific E3 ubiquitin ligases MAFbx/Atrogin1 and MuRF1. BRD4
recruitment at the E3 ubiquitin-ligases MuRF1 and MAFbx/
Arogin1 genes was reduced in skeletal muscles of (+)-JQ1-treated
C26-tumor-bearing mice (Fig. 4d, e). Likewise, BRD4 occupancy
at the GABARAPL1 gene increased in muscles from cachectic
mice and was reduced upon (+)-JQ1-treatment (Fig. 4f). To
explore the molecular mechanisms underlying MAFbx/Atrogin1,
MuRF1, and GABARAPL1 transcriptional regulation, we inves-
tigated RNA Polymerase II (RNAPolII) recruitment at these loci.
RNAPolII association at the promoters of MAFbx/Atrogin1,
MuRF1, and GABARAPL1 increased in muscles from (−)-JQ1-
treated C26-tumor-bearing mice when compared to control
muscles, in agreement with the enhanced RNA transcript
levels (Fig. 3c, d, g). Conversely, RNAPolII occupancy at these
promoters was comparable in skeletal muscles from (+)-JQ1-
treated C26-tumor-bearing mice and control muscles, suggesting
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that BRD4 blockade prevented RNAPolII association at these
promoters (Fig. 4g). Taken together, these findings suggest that
BRD4 directly takes part in the transcriptional regulation of
MAFbx/Atrogin1, MuRF1, and GABARAPL1 genes, and that its
engagement correlates with RNAPolII recruitment at regulatory
regions of atrogenes and autophagy genes. Because of BRD2
overlapping regulation in several subsets of BRD4 targets30,31, we
investigated BRD2 ability to engage MAFbx/Atrogin1, MuRF1,
and GABARAPL1 loci, during cachexia. BRD2 associates with
MAFbx/Atrogin1 and GABARAPL1 promoters during cachexia,
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and this association is abrogated by (+)-JQ1 treatment (Supple-
mentary Fig. 6). However, BRD2 was not recruited at MuRF1
promoter and enhancer regions (Supplementary Fig. 6), suggest-
ing that BRD4 is the principal BET protein-regulating MuRF1
transcription, during cachexia.
JQ1 perturbs the expression of tumor pro-cachectic factors.
Since pro-inflammatory cytokines play a critical role in the onset
of cancer cachexia, we measured mRNA levels of IL6, TNFα,
IL1β, and PTHrP32,33 in C26 tumors isolated from mice treated
with vehicle, (−)-JQ1 and (+)-JQ1 (20 and 50 mg/kg/day). No
significant differences in IL1β (p= 0.7705, one-way ANOVA) and
TNFα (p= 0.1252), one-way ANOVA) transcript levels were
detected (Supplementary Fig. 7a, b). TNFα-dependent NFκB
-p65 (Ser 536) phosphorylation was also unaffected by (+)-JQ1
treatment in TA skeletal muscle (Supplementary Fig. 7c). In
contrast, IL6 (p< 0.0001, one-way ANOVA) and PTHrP (p=
0.0002, one-way ANOVA) levels were significantly decreased in
tumors from (+)-JQ1-treated mice, when compared with tumors
from vehicle- and (−)-JQ1-treated animals (Fig. 5a; Supplemen-
tary Fig. 7d).
To assess the function of BRD4 in IL6 transcriptional
regulation in C26 cells, we initially employed an in vitro
approach. JQ1 treatment as well as BRD4 knockdown resulted
in a prompt reduction of IL6 levels in C26 cells (Fig. 5b, c).
Chromatin immunoprecipitation assays in tumors showed that
BRD4 is recruited at the IL6 promoter and that (+)-JQ1 treatment
impairs BRD4 occupancy, suggesting that (+)-JQ1 plays a
primary role in hindering IL6 expression in C26 adenocarcinoma
tumors (Fig. 5d). Accordingly, we found that (+)-JQ1 adminis-
tration significantly (p< 0.0001, one-way ANOVA) reduced IL6
circulating levels, which were significantly (p< 0.0001, one-way
ANOVA) elevated in tumor-bearing mice treated with either
vehicle or (−)-JQ1, when compared to control mice (Fig. 5e).
IL6 induces signal transducer and activator of transcription 3
(STAT3) phosphorylation and STAT3-dependent activation of
target genes34. In TAs of (+)-JQ1-treated tumor-bearing mice,
STAT3 activatory phosphorylation (p< 0.0001, one-way
ANOVA) and expression of the STAT3 target suppressor of
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cytokine signaling 3 (SOCS3) (p< 0.0001, one-way ANOVA)
were significantly reduced (Fig. 5f). JQ1 treatment concurrently
decreased PTHrP mRNA expression in C26 cells (Supplementary
Fig. 7e). BRD4 occupied the PTHrP promoter in tumors from
(−)-JQ1-treated animals, and this association was abrogated in
tumors isolated from (+)-JQ1-treated animals (Supplementary
Fig. 7f). Accordingly, plasma levels of PTHrP were also reduced
upon (+)-JQ1 treatment (Supplementary Fig. 7g). Together with
BRD4, BRD2 was implicated in modulation of the inflammatory
response in bone marrow-derived macrophages and in sepsis35,36
and in the regulation of metabolic pathways37. Thus, we
investigated whether BRD2 contributed to the transcriptional
regulation of pro-cachectic factors such as IL6 or PTHrP in the
tumor. We have found that BRD2 is recruited at IL6 and PTHrP
promoters and (+)-JQ1 treatment reduces its engagement,
although less effectively, when compared to BRD4 (Supplemen-
tary Fig. 8). Overall, these data support a role for BET proteins in
modulating circulating IL6 and PTHrP levels and suggest that the
BET inhibitor (+)-JQ1 restrains cancer cachexia through the
reduction of IL6 and other cachectic factors.
IL6-mediated AMPK activation promotes muscle atrophy.
Activation of the 5′-adenosine monophosphate-activated protein
kinase (AMPK) signaling pathway has recently been implicated in
cancer cachexia38–40. AMPK plays a crucial role in energy
homeostasis and is a sensor of the metabolic state during cancer
cachexia38. Notably, AMPK phosphorylates FoxO3 at residues
Thr179, Ser399, Ser413, Ser555, Ser588, and Ser62641. Increasing
lines of evidence hint for a central role of IL6 in AMPK activa-
tion: IL6 knockout mice display decreased AMPK activation in
skeletal muscle and adipose tissue42, IL6 treatment leads to
AMPK activation in C2C12 myotubes38, and systemic adminis-
tration of IL6 receptor antibody attenuates AMPK activation in
ApcMin/+ cachectic mice43. To in vitro recapitulate the impact of
IL6 on muscle cells, we treated C2C12 myotubes with IL6 and
observed myotube atrophy, as revealed by a reduction in myotube
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diameter (Fig. 5g; Supplementary Fig. 9a). AMPK blockade by
Compound C hampered IL6 pro-atrophic effects. Moreover,
Compound C administration reduced IL6-induced FoxO3
(Ser413) phosphorylation and MAFbx/Atrogin-1 upregulation
(Fig. 5h; Supplementary Fig. 9b).
To shed light on the in vivo molecular mechanisms underlying
the AMPK/FoxO3 interplay, we analyzed AMPK(Thr172) and
FoxO3(Ser413) phosphorylation levels in TA muscles from
vehicle, (−)-JQ1 and (+)-JQ1 tumor-bearing mice. AMPK was
strongly activated in muscles of C26 vehicle and (−)-JQ1-treated
tumor-bearing mice; the increase in AMPK(Thr172) phosphor-
ylation paralleled a concurrent dramatic increase in FoxO3
(Ser413) phosphorylation. Both p-AMPK(Thr172) and p-FoxO3
(Ser413) levels were comparable in muscles from (+)-JQ1-treated
C26-tumor-bearing mice and control animals (Fig. 6a). We
further investigated alternative mechanisms underlying FoxO3
modulation and asked whether the Akt/FoxO3 and myostatin/
Smad3 axis were affected by implanted C26 colon carcinoma cells
and JQ1 administration. Total FoxO3 protein levels were
modestly increased in TA muscles from C26-tumor-bearing
mice (Fig. 6a), in agreement with previous reports44,45. Akt-
phosphorylated FoxO3(Ser253) was not affected by tumor
implantation as well as by (+)-JQ1 treatment (Fig. 5a). Con-
sistently, p-Akt(Ser473) was comparable in the four animal
groups (Supplementary Fig. 10a). Myostatin and Smad3 phos-
phorylation were also similar in control, vehicle, and (+)-JQ1-
treated muscles from C26-tumor-bearing mice (Supplementary
Fig. 10b, c).
While Akt-mediated phosphorylation modulates FoxO3
cellular localization, AMPK-dependent phosphorylation appears
to modulate FoxO3 transcriptional activation and to promote
transcription of a subset of FoxO3 targets, as reported in mouse
embryonic fibroblasts (MEFs)41. We asked whether increased
AMPK-mediated FoxO3 phosphorylation affected FoxO3 cellular
compartmentalization in skeletal muscle. p-FoxO3(Ser413) was
primarily localized in the nucleus of control TA myofibers, and its
levels considerably increased during cancer cachexia. Likewise,
while being mainly cytoplasmic, the nuclear fraction of p-AMPK
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Fig. 8 JQ1 administration blocks epididymal adipose tissue wasting. a Representative western blot and densitometric analysis of ATGL expression in
epididymal adipose tissue (eAT) from control animals and C26-tumor-bearing mice treated with vehicle, (−)-JQ1, and (+)-JQ1 (animals per group: n= 3).
Data represent means± SD. b Representative western blot and densitometric analysis of the nuclear and transcriptionally active fragment of SREBP-1
(nSREBP-1) in the eAT of control and C26-tumor-bearing mice treated with vehicle, (−)-JQ1, and (+)-JQ1. Four animals were used for each experimental
condition. Data represent means± SD. c, d Total RNA was extracted from eAT of control and C26-tumor-bearing mice (animals per group: n= 5) treated
with vehicle or JQ1 (−/+) and expression levels of ACCα and FAS were measured by quantitative RT-PCR. Data represent means± SD. e Representative
western blot and densitometric analysis of p-AMPK (Thr172) in eAT of the six experimental groups described in a. Four mice were used for each
experimental group. Data represent means± SD. f Representative western blot and densitometric analysis of ACCα protein expression and p-ACCα
inhibitory phosphorylation (Ser79) in eAT of control and C26 tumor-bearing mice (animals per group: n= 4) treated with vehicle or JQ1 (−/+). Data
represent means± SD. Statistical analysis was performed by using one-way ANOVA followed by Tukey’s post hoc test. *p< 0.05; **p< 0.01; ***p< 0.001.
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(Thr172) augmented in muscles from cachectic mice and (+)-JQ1
treatment prevented p-AMPK(Thr172) and p-FoxO3(S413)
nuclear accumulation (Fig. 6b). Immunostaining of TA muscle
sections confirmed the nuclear localization of p-FoxO3(Ser413)
(Fig. 6c) and p-AMPK(Thr172) (Supplementary Fig. 5d) in
muscles from cachectic animals. Positive staining was limited to
few spared nuclei in control mice, but dramatically increased in
muscles from vehicle-treated C26-tumor-bearing mice. Both
p-AMPK(Thr172) and p-FoxO3(Ser413) staining was reduced
in (+)-JQI-treated animals (Fig. 6c; Supplementary Fig. 10d).
AMPK and FoxO3 regulate the transcription of catabolic
genes. FoxOs transcription factors are a central node in skeletal
muscle during cancer cachexia, coordinating gene networks that
lead to muscle wasting46. Judge et al. (2014) identified a subgroup
of FoxO-regulated genes that are upregulated in response to C26
tumor burden and are involved in muscle wasting47 (Judge et al.,
2014). We analyzed BRD4 engagement for this subset of FoxO-
regulated genes at regulatory regions active in skeletal muscle,
defined by the presence of DNAse I hypersensitive sites (DHS)
(data obtained from Encode Project). BRD4 tag density
distribution on DHS sites of this subgroup of FoxO-regulated
genes revealed an increased BRD4 occupancy during cancer
cachexia, which was abrogated by (+)-JQ1 treatment (Fig. 7a).
These data indicate that BRD4 engagement increases at
regulatory regions of a subgroup of wasting-related and FoxO-
regulated genes during cachexia and that BRD4 association is
challenged by (+)-JQ1. We therefore investigated FoxO3
recruitment to MAFbx/Atrogin1, MuRF1, and GABARAPL1
promoters in skeletal muscles from control and (−)-JQ1 and
(+)-JQ1-treated C26-tumor-bearing mice by ChIP qPCR. We
observed that FoxO3 recruitment at these promoters was
remarkably increased in muscles from tumor-bearing mice, while
FoxO3 occupancy at these sites was similar in muscles from
control and (+)-JQ1-treated tumor-bearing mice (Fig. 7b). Taking
into account that p-AMPK(Thr172) increased nuclear localiza-
tion during cachexia, we decided to elucidate whether nuclear
p-AMPK(Thr172) may be recruited on the chromatin, and we
also queried promoter regions of pro-atrophy genes by ChIP. We
observed that p-AMPK(Thr172) occupies the MAFbx/Atrogin1,
MuRF1, and GABARAPL1 promoters and that its association
increased during cachexia. Conversely, (+)-JQ1 administration to
C26-tumor-bearing mice led to a reduced association of p-AMPK
(Thr172) at these chromatin regions (Fig. 7c).
To investigate whether AMPK-dependent FoxO3 phosphor-
ylation plays a role in FoxO3 transcriptional activation, we
employed a FoxO3 mutant in which the AMPK-phosphorylated
residues are mutated to alanines (FoxO3-6A). Myogenic C2C12
cells stably overexpressing FoxO3-WT or FoxO3-6A were
differentiated for 3 days in differentiation medium to form
myotubes, which were then starved in low glucose medium for
24 h. Immunofluorescence assays showed that the six mutations
do not affect FoxO3’s ability to translocate to the nucleus upon
starvation (Supplementary Fig. 11a–c). Foxo3-WT overexpressing
cells had a significantly (p< 0.0001, one-way ANOVA) reduced
diameter following starvation, while FoxO3-6A overexpressing
myotubes were protected from atrophy (Fig. 7d; Supplementary
Fig. 11d). In contrast to FoxO3-WT overexpressing cells, FoxO3-
6A overexpressing myotubes failed to up-regulate MuRF1 and
GABARAPL1 transcripts during starvation (Fig. 7e). Likewise,
treating differentiated FoxO3-WT and FoxO3-6A overexpressing
myotubes with conditioned medium from C26 cells (C26-CM)
showed that FoxO3-6A overexpressing cells were resistant to
C26-CM induced myotubes atrophy (Supplementary Fig. 11e).
Overall, these data suggest that phosphorylation of these sites
plays a crucial role in FoxO3 activation during pro-atrophic
conditions.
JQ1 treatment spares epididymal adipose tissue wasting.
To assess whether the intraperitoneal administration of BET
inhibitors impacted other tissues in a more systemic manner, we
analyzed epididymal adipose tissue, which together with skeletal
muscle was spared by (+)-JQ1 administration (Fig. 2d). In
response to circulating inflammatory cytokines, the levels of
Control Cachexia
0
2
4
6
p-FoxO3 (Ser413)
**
p-
Fo
xO
3/
G
AP
DH
 (a
.u.
)
Control Cachexia
0
1
2
3
4
5
p-AMPK (Thr172)
*
p-
AM
PK
/G
AP
DH
 (a
.u.
)
pFoxO3
ser413
pAMPK
thr172
GAPDH
pFoxO3
ser413
pAMPK
thr172
GAPDH
Controls
Colon
cancer patients
100
50
37
100
50
37
Controls
Pancreatic
cancer patients
a
b
Fig. 9 Cachectic cancer patients show increased levels of p-FoxO3Ser413 and p-AMPKThr172 in rectus abdominis muscle. a p-FoxO3 (Ser413) and
p-AMPK (Thr172) levels were measured by immunoblot in rectus abdominis muscles from non-neoplastic patients (n= 8) and cachectic cancer patients
(n= 15). GAPDH serves as loading control. Data are presented in scatter dot plot, lines at means± SD. Statistical analysis was performed by using
Student’s unpaired t-test. *p< 0.05; **p< 0.01. b Representative western blots from non-neoplastic patients (controls), colon cancer, and pancreatic
cancer patients are shown
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01645-7 ARTICLE
NATURE COMMUNICATIONS |8:  1707 |DOI: 10.1038/s41467-017-01645-7 |www.nature.com/naturecommunications 11
lipolytic enzymes increase to mobilize lipids and induce fat
depletion during cancer cachexia47,48. (+)-JQ1 treatment
prevented the upregulation of the lipase ATGL occurring in
epididymal adipose tissue of vehicle and (−)-JQ1-treated
C26-tumor-bearing mice (Fig. 8a). Moreover, BET blockade by
(+)-JQ1 favored the activating cleavage of the lipogenic tran-
scription factor sterol regulatory element-binding protein 1
(SREBP-1), which was suppressed in adipose tissue from
cachectic mice (Fig. 8b). SREBP-1 promotes the expression of
transcriptional targets as acetyl CoA carboxylase (ACC1) and
fatty acid synthase (FASN), to stimulate fatty-acid synthesis49.
Accordingly, ACC1 and FASN transcripts decreased in vehicle
and (−)-JQ1-treated tumor-bearing mice. Transcript levels were
comparable in control and (+)-JQ1-treated tumor-bearing mice
(Fig. 8c, d). Because of AMPK crucial role as a metabolic sensor
driving lipolysis, lipid mobilization, and biosynthesis39,49,50, we
investigated AMPK activation in epididymal adipose tissue in the
six animal groups. AMPK(Thr172) phosphorylation dramatically
increased in C26-tumor-bearing mice38. Similarly to skeletal
muscle, (+)-JQ1 administration prevented p-AMPK(Thr172)
increase in white fat (Fig. 8e). AMPK phosphorylates the rate-
limiting enzyme in fatty-acid synthesis acetyl CoA carboxylase
alpha (ACCα), which is consequently converted to an inactive
form. In agreement with these findings, AMPK-dependent
ACCα phosphorylation increased in C26-tumor-bearing mice
treated either with vehicle or (−)-JQ1, but was maintained at
control levels in (+)-JQ1-treated C26-tumor-bearing mice.
Moreover, ACCα total protein levels decreased in vehicle and
(−)-JQ1-treated mice, but not upon (+)-JQ1 treatment, in
agreement with the analysis of SREBP-1 active form and ACC
transcript (Fig. 8f). Collectively, these data suggest that (+)-JQ1
administration impairs white fat loss in cachexia through the
modulation of AMPK and key actors in the lipogenic and lipolytic
pathways.
p-AMPK and p-FoxO3 increase in muscles of cachectic
patients. To evaluate whether the levels of p-AMPK(Thr172) and
p-FoxO3(Ser413) are upregulated in skeletal muscle from cancer
cachexia patients, we obtained muscle biopsies from cachectic
patients affected by malignancies (colorectal and pancreatic
cancers) in which cachexia has a 80% prevalence. Cancer patients
were designated as cachectic according to the definition by
Fearon et al.51. Immunoblot analysis of muscle biopsies revealed
that both p-FoxO3(Ser413) (p= 0.0058, unpaired t-test) and
p-AMPK(Thr172) (p= 0.014, unpaired t-test) levels were
significantly higher in rectus abdominis muscle biopsies of
cachectic cancer patients than in age-matched non-neoplastic
patients (Fig. 9a, b; Supplementary Table 1). The results were
comparable between the two cancer types and no sex-related
differences were detectable, suggesting that the activation of
AMPK/FoxO3 axis in skeletal muscle is a common event in
cachectic cancer patients.
Discussion
Previous reports5,6 and findings presented in this article highlight
that preventing muscle and adipose tissue loss is a key element to
prolong survival in experimental cancer cachexia models. Thus,
development of therapies targeting cachexia should be a major
goal to enhance cancer patients’ quality of life, response to
chemotherapy, and lifespan extension.
In this study, we pointed at BET blockade as a potential
therapeutic approach to counteract cancer cachexia through two
coordinated mechanisms, which directly target key players
controlling muscle atrophy and pro-cachectic factors expression
(Fig. 10).
JQ1 derivatives are currently in clinical trials as antineoplastic
agents and show early encouraging results with leukemia
and lymphoma patients52. Nevertheless, innate or induced
resistance to BET inhibitors has been described53–56 and novel
combinatorial pharmacological approaches are developed. These
approaches build on the mechanistic rationale that BET inhibitors
resistance derives from acquired bromodomain-independent
functions and by increased BRD4 phosphorylation levels. In
this scenario, our results highlight that BET inhibitors may result
beneficial independently of their direct antineoplastic activity,
owing to their ability to restrain the expression of catabolic
factors in skeletal muscle tissue.
At the onset of cancer cachexia, direct BRD4 and BRD2
recruitment at muscle catabolic genes is likely favored by local
increase in histone acetylation, in concert with sustained
engagement of transcription factors (e.g., FoxO3) and co-factors
at chromatin regulatory regions. FoxO3 was shown to increase
histone acetylation at its target loci, in DLD1-F3 cells
overexpressing a constitutively active form of FoxO357,58. We
speculate that increased FoxO3 recruitment and histone acetyla-
tion promote BRD4 association, which in turn favors RNA PolII-
mediated transcription. Interestingly, in a subset of genes such as
MuRF1 and MAFbx/Atrogin-1 (Fig. 3), BRD4 also occupies
regions of the gene body in muscles from C26-tumor-bearing
mice, as previously reported for BRD4 targets in other
experimental models59. Notably, FoxO transcription factors are
acetylated at multiple lysine residues and this could represent an
additional means of direct BRD4 and BRD2 recruitment, as
previously described for the p65 subunit of NFkB, Twist60, and
STAT330. We propose that in cancer cachexia, increased FoxO3
occupancy at pro-atrophic genes MuRF1, MAFbx/Atrogin-1,
and GABARAPL1 is promoted by AMPK-mediated FoxO3
phosphorylation, which is ultimately induced by increased
systemic IL6 levels and AMPK activation in skeletal muscle
(Fig. 10). Beside local effects on skeletal muscle, systemic levels of
pro-cachectic modulators are also affected by (+)-JQ1 treatment.
We showed a direct involvement for BRD4 and BRD2 in IL6 and
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PTHrP transcriptional regulation in C26 tumors. IL6 and PTHrP
appear to promote cancer cachexia through non-overlapping
pathways, with a prominent role for PTHrP in hypercalcemia33
and adipose tissue wasting61. Following (+)-JQ1 treatment,
IL6 and PTHrP expression is reduced in tumors derived from
C26 cells, suggesting that (+)-JQ1 modifies the tumor transcrip-
tional program and prevents pro-cachectic factors upregulation,
without affecting tumor mass. Notably, by impacting two or more
mediators of cancer cachexia, (+)-JQ1 treatment may hamper
adipose and muscle tissue wasting through distinct, but coordi-
nated mechanisms.
Importantly, the systemic modulator IL6 has an impact on
local muscular events through the IL6/AMPK/FoxO3 axis and
likewise on other districts, such as adipose tissue. Because of
the multifaceted nature of the disease and IL6 multisystemic
functions, it is challenging to estimate the weight of local vs.
systemic factors modulation. In this scenario, tempering multiple
BET-regulated targets in different districts may be the key for an
effective attenuation of cachexia symptoms.
We have focused our attention on pro-cachectic factors
secreted by the tumor; nevertheless, systemic (+)-JQ1 delivery
may concurrently reduce the transcription of pro-cachectic
factors in other tissues and districts of the host. Cancer
cachexia is a multi-organ metabolic syndrome, and since (+)-JQ1
is systemically delivered, its potential impact on tumor, inflam-
matory cells, adipose tissue, and skeletal muscle may synergisti-
cally be involved in cancer cachexia blockade.
We revealed a direct role for BET proteins both in skeletal
muscle and in the tumor, by showing direct recruitment of BRD4
and BRD2 at a subset of pro-atrophic genes and pro-cachectic
mediators.
Several reports link increased IL6 levels with AMPK activa-
tion38,42,43. Here we show that IL6-dependent AMPK activation
signals to the nucleus and translates into FoxO3-dependent
transactivation of catabolic genes. Notably, we discovered that
AMPK is directly recruited to regulatory regions of catabolic
genes. Compelling lines of evidence have shown that AMPK
translocates to the nucleus, in several physiological and
pathological conditions62,63. AMPK takes part in metabolism
reprogramming, not only through direct regulation of metabolic
enzymes, but also by influencing transcriptional regulation.
AMPK phosphorylates a number of transcription factors and
chromatin factors64,65, as well as histone H2B at lysine 36, and
directly associates to chromatin of stress-induced genes in MEFs
cells66. Our findings reveal a key role for AMPK recruitment
at chromatin regions of muscle catabolic genes, supporting
the relevance of AMPK nuclear and chromatin functions in
metabolism regulation. Importantly, we show that AMPK
activation and AMPK-dependent FoxO3 phosphorylation are
upregulated in cachectic cancer patients, hinting for a conserved
role of AMPK/FoxO3 interplay in cancer cachexia.
Overall, BET inhibitors represent a promising strategy
to coordinately counteract muscle wasting, by decreasing
inflammation and by preventing activation of the muscle
catabolic program.
Methods
Study design. The pre-specified objective of the research was to evaluate whether
BETs inhibition with the small molecule (+)-JQ1 was able to counteract cancer
cachexia. This pre-specified hypothesis led us: (i) to investigate BRD4 contribution
to muscle atrophy secondary to cancer and BRD4 role in regulating pro-cachectic
factors levels and (ii) to dissect BRD4 interplay with FoxO3 and IL6/AMPK
signaling in skeletal muscle. We studied experimental models of cancer cachexia,
patients’ muscle biopsies and cell culture assays.
A priori determination of sample size was calculated by analyzing the published
data26 and by evaluating the number of animals per group used for similar
experiments. Prior knowledge of the growth rate and variability of tumor models
was also considered for the establishment of sample size.
The minimal sample size for morphological, western blot, and ChIP analysis
was generally 3–5 animals per group, whereas functional and mRNA evaluations
were assessed on 8–10 animals per group. For all in vitro data, the number of
experiments is defined in the figure legend. In vitro experiments were
independently repeated at least three times. In order to minimize the intragroup
biological variation, all the experiments were performed in the same physiological
conditions, by using 8-week-old male mice.
Final endpoints were determined prospectively and were based on the degree of
cachexia and tumor volume of the vehicle-treated tumor-bearing mice. Exclusion
criteria for animals were applied in case of death, cannibalism, and the presence of
severe clinical alteration of vital physiological functions and ulceration induced by
the tumor mass. Exclusion criteria for samples were applied in case of histological
artifacts (freeze- and cut-damaged tissues), RNA and protein degradation, assessed
by gel electrophoresis. Mice purchased from Charles River were randomly allocated
to six different experimental groups. In vivo experiments and animal manipulation
were not blinded. However, blind evaluation was performed for tissue weight,
morphological analysis, mRNA estimation, and protein quantification of mouse-
derived tissue samples. Statistical analysis was conducted upon verification of the
Normality assumption by using the Kolmogorov–Smirnov test (where applicable).
The similarity of variance among the experimental groups was also verified.
Cell culture and materials. MAC16, C26, and B16 cells were a kind gift of Drs
Tisdale and Russell (School of Life & Health Sciences, Aston University
Burmingham, UK), Professor Mario P. Colombo (IRCCS National Cancer
Institute, Milano, Italy), and Professor F. Cavallo (Department of Molecular
Biotechnology and Health Science, University of Turin, Italy), respectively. PC-3M
and A375M were obtained from MD Anderson Cancer Center, MKN-1 from Riken
BioResource Center (Japan), LLC, 4T1, C32, and A2058 cells were from ATCC.
Cell lines were assessed monthly for Mycoplasma contamination with MyocAlert
Mycoplasma detection kit (Euroclone, Italy).
MAC16, 4T1, A375M, MKN-1, and PC-3M cells were cultured in RPMI
(Sigma, Italy), whereas C26, LLC, B16, and A2058 cells were cultured in high-
glucose Dulbecco’s Modified Eagle’s medium (DMEM; Euroclone, Italy). All
culture media were supplemented with 10% fetal bovine serum (Euroclone, Italy)
and Pen/Strep solution (penicillin 100 U/ml and streptomycin 0.1 mg/ml)
(Lonza, Euroclone, Italy) and maintained at 37 °C with a humidified atmosphere
of 5% CO2. Cell sensitivity to (+)-JQ1 was evaluated by seeding 100,000 cells in
35 mm dishes; each cell line was then treated with three different doses of (+)-JQ1
for 72 h. After 72 h, the cells were colored with trypan blue and viable cells
were counted, to evaluate cell viability. Cell viability was represented showing
the percentage of viable cells (control cell= 100% viability). C26 were treated with
different concentration of (+)-JQ1 or (−)-JQ1 for 48 h before RNA extraction.
C2C12 myoblast cells (ATCC) were cultured in DMEM without Na-Pyruvate
(Sigma, Italy) supplemented with 20% FBS, 2 mM L-glutamine, and 100 U/ml
penicillin and 0.1 mg/ml streptomycin (Euroclone, Italy) at 37 °C and 5% CO2 and
induced to differentiate by switching to DM medium (DMEM supplemented with
2% horse serum) for 4 days.
Starvation was induced by switching myotubes in DMEM with 2.5 mM glucose
(Invitrogen, Italy) and 0.1% horse serum (Invitrogen, Italy).
C2C12 were treated with 20 ng/ml rIL-6 (Abcam, UK) and/or 10 μM
Compound C (Abcam, UK) diluted in DM medium.
Lentivirus production and plasmids. Lentiviral vectors were produced by
transient co-transfection of pLKO, psPAX2 (#12260 Addgene), and VSVG (#8454
Addgene) plasmids into HEK293T. pLKO.1 plasmid targeting murin BRD4 was
kindly provided from Dr. Hernando. pBabe-FoxO3WT and pBABE-FoxO3-6A
were transferred from pECE-Flag-FoxO3-WT (#8360 Addgene) and pCDNa-Flag-
FoxO3-6A (#24382 Addgene) in pCRII-TOPO by using TOPO TA Cloning
kit (Life Technologies, Italy), and then sublconed in pBabe retroviral vector,
through SalI digestion.
Retroviruses were produced by transient co-transfection of pCL-ECO
(plasmid #12371, Addgene) and pBABE-Empty (plasmid #1764, Addgene) or
pBABE-FoxO3-WT or pBABE-FoxO3-6A in HEK293T cells.
Virus was harvested 48 h post transfection and infections were carried out
by spinoculation at 3000 rpm for 90 min, in presence of 4 μg/ml polybrene
(Santa Cruz). Infected cells were selected with 4 μg/ml (C26 cell line) or 2 μg/ml
(C2C12 cell line) puromycin (Sigma, Italy) for a week.
RT-PCR and real-time PCR. Total RNA from either snap-frozen tissues or
cells was isolated using Trizol (Sigma, Italy) according to the manufacturer’s
instructions. After DNAse treatment (Ambion, Life Technologies, Italy), RNA was
purified with RNA clean up Kit (Zymo, Italy), reverse transcribed to cDNA with
the High-Capacity cDNA Reverse Transcription Kit (Applied Bio-System), and
subjected to qPCR analysis. Primers were designed to amplify regions of 80–120 bp.
Oligonucleotides sequences used in qRT-PCR are reported in Supplementary
Table 2. Quantitative PCR was performed in triplicates using SYBR green IQ
reagent (Bio-Rad Laboratories, Italy), with CFX Connect detection system (Bio-
Rad Laboratories, Italy).
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ChIP and ChIP-seq. Chromatin isolated from muscles or tumors was subjected to
ChIP and ChIP-seq assays according to Savic et al.67. Briefly, frozen tissues were
pulverized in Covaris tissue TUBEs (Covaris 520001) using a chilled hammer on a
cold metallic block, in dry ice. Powdered tissue was transferred in a glass, where it
was resuspended in PBS, cross-linked in 1% formaldehyde (Sigma, Italy) for
15 min. After blocking cross-link with 0.125 M glycine for 5 min and washes with
PBS plus protease and phosphatase inhibitors, pellet was resuspended in Farnham
buffer (5 mM PIPES pH 8.0; 85 mM KCl; 0.5% NP-40) and briefly homogenized
with a tissue homogenizer.
Cells were subsequently lysed in RIPA buffer (1× PBS; 1% NP-40; 0.5% sodium
deoxycholate; 0.1% SDS). For each antibody,100 mg of starting tissue was used.
Chromatin was sonicated to fragments length of ~0.5 kb and immunoprecipitated
with 3.5 µg of rabbit IgG or antibodies listed in Supplementary Table 4.
Immunoprecipitation procedures were performed as in Proserpio et al.17.
ChIP primers are listed in Supplementary Table 3. Quantitative real-time PCR was
performed using SYBR green IQ reagent (Bio-Rad Laboratories, Italy) with CFX
Connect detection system (Bio-Rad Laboratories, Italy). For ChIP-seq, 10 ng
immunoprecipitated DNA fragments were used to prepare libraries with the
NEBNext RNA Library Prep Kit (New England Biolabs) and the Ovation SP
Ultralow DR Multiplex System (NuGEN), following the manufacturer’s protocol.
Libraries were sequenced for 50 cycles on a HiSeq 2000 or HiSeq2500 Illumina
instrument. Peaks distribution was plotted using PAVIS and Gene Ontology
analysis was performed using DAVID 6.8 bioinformatic resource.
Animals experimental design. Eight-week-old male BALB/c mice (Charles River,
Italy) were housed in groups of five and maintained under controlled temperature
(20± 1 °C), humidity (55± 10%), and illumination (12/12 h light cycle with lights
on at 07:30 am). Food and water were provided ad libitum. All mice were held in
quarantine for 2 weeks before the experiments. Tubes for tunneling and nesting
materials (paper towels) were routinely placed in all cages as environmental
enrichment. All procedures involving animal care or treatments were approved by
the Italian Ministry of Health and performed in compliance with the guidelines of
the Italian Ministry of Health (according to the Legislative Decree 116/92), the
Directive 2010/63/EU of the European Parliament and the Council of 22 September
2010 on the protection of animals used for scientific purposes.
Tumor-bearing mice received 105 C26 colon carcinoma cells in PBS by dorsal s.
c. injection as previously reported15. Control mice were inoculated with PBS.
Animals were then randomized and divided into six groups: control (mice without
tumor-cell inoculation, treated with vehicle), C26 + Veh (C26-bearing mice treated
with vehicle), C26+(−)-JQ1-20 (C26-bearing mice, 20 mg/kg body weight of the
inactive JQ1 enantiomer), C26+(−)-JQ1-50 (C26-bearing mice, 50 mg/kg body
weight of the inactive JQ1 enantiomer), C26+(+)-JQ1-20 (C26-bearing mice,
20 mg/kg body weight of the active JQ1 enantiomer), and C26+(+)-JQ1-50
(C26-bearing mice, 50 mg/kg body weight of the active JQ1 enantiomer). Active
and inactive JQ1 enantiomers were dissolved in vehicle (10% 2-hydroxypropyl-β-
cyclodextrin, 10% DMSO) at a final concentration of 5 mg/kg, and daily
administered by i.p. injections during the whole experimental period. Animal
weight and food intake were recorded daily. Twelve days after C26 implantation,
the mice were deeply anesthetized using tribromoethanol (250 mg/kg) and the
blood was collected into EDTA (1 mg/ml blood) for plasma analyses. Subsequently,
mice were decapitated and their tissues quickly collected. In particular, skeletal
muscles, adipose tissue, and C26 tumors were excised, weighed, and frozen in
cooled isopentane with liquid nitrogen and stored at −80 °C for subsequent
biochemical and morphological analyses. In survival studies, when treatment was
started at moderate cachexia, (+)-JQ1 (20 mg/kg body weight) or vehicle
administration began when C26-tumor-bearing mice average weight loss was 10%.
Animal weight and food intake were recorded daily. For B16 melanoma-induced
cachexia, a suspension of 105 B16 cells in PBS was subcutaneously injected in
C57BL/6 mice. Ten days after tumor-cell inoculation, the animals received a daily
dose of (+)-JQ1 (20 mg/kg) or vehicle (10% 2-hydroxypropyl-β-cyclodextrin, 10%
DMSO). The mice were sacrificed 3 weeks after tumor implantation.
Treadmill test. Animals were subjected to an exercise tolerance test every week,
starting from the initial day of tumor cell inoculation and JQ1 treatment. Briefly,
the mice were acclimatized to treadmill running with a 10-min run at a constant
speed of 6 m/min for five consecutive days prior to the first exercise. During the test
sessions, mice were run at an initial speed of 6 m/min, and every 2 min speed was
increased by 2 m/min until exhaustion. The animals were encouraged to run with
an electrical shock grid at the back of the treadmill (1.5 mA, 200 ms pulses, 4 Hz).
The study was performed until the mouse was exhausted as defined by remaining
on the electrified grid for at least 5 s. The first exercise test was used to set the
baseline of each experimental group.
Interleukin-6 detection. Plasma IL-6 concentration was measured on plasma
samples by ELISA kit (Invitrogen Life Technologies, Italy) according to the
manufacturer’s instructions.
In vitro protein degradation assay. Fast MyHC degradation was assayed
according to a previously described protocol68. Briefly, TA samples were
homogenized in ice cold 0.01 M Tris-HCl (pH 7.4), 0.150 M sucrose. Total protein
concentration was performed by the method of Lowry et al.68. Homogenate (30 µg)
was used for each reaction. Samples were incubated at 37 °C, the incubation was
blocked by adding an equal volume of sample buffer (0.125M Tris-HCl containing
10% SDS, PMSF, protease inhibitor cocktail, pH 6.8), at different time points.
The samples were boiled for 3 min and loaded onto acrylamide gel for western
blot analysis.
Western blot. For total lysate preparation, mouse tissues (TA muscles, epididymal
adipose tissue, and C26 tumors) and cultured cells were homogenized in a
homogenization buffer (0.01 M Tris-HCl, 0.001M CaCl2, 0.15M NaCl, 1 mM
PMSF, protease inhibitor cocktail, and phosphatase inhibitor cocktail, pH 7.5). The
homogenate was then lysed by sonication. Cytosolic and nuclear fractionation was
prepared as in Dimauro et al.69. Protein concentration was assessed by the method
of Lowry et al.68. Samples were boiled for 3 min before loading to the SDS-PAGE.
Proteins (30 µg) were resolved by 12% (for caspase-3, LC3b, interleukin-6, H3, and
PTHrP), 10% (for Myc, Atrogin-1, Beclin-1, AMPK, Akt, Myostatin, ATGL, and
SMAD3), and 7% (for MyHC fast, MyHC slow, Ulk, FoxO1, FoxO3, STAT3,
SREBP-1, and ACC), and SDS-PAGE at 30 mA (constant current) for 60 min.
Proteins were transferred onto nitrocellulose membrane using the trans-blot turbo
transfer system (Bio-Rad Laboratories, Italy) for 10 min at room temperature.
The nitrocellulose membrane was blocked with 5% fat-free milk or 3% BSA in
Tris-buffered saline (0.138M NaCl, 0.027 M KCl, 0.025 M Tris-HCl, and 0.05%
Tween-20, pH 6.8) at room temperature, and probed at 4 °C overnight with
primary antibodies followed by incubation for 1 h with horseradish peroxidase-
conjugated secondary IgG antibodies (Bio-Rad Laboratories, Italy). The
nitrocellulose membrane was then re-probed with anti-Vinculin, anti-GAPDH,
anti-Actin, or anti-H3 antibodies. Bound antibodies were visualized using Clarity
Western ECL substrate (Bio-Rad Laboratories, Italy) and image acquisition
was performed through ChemiDoc MP system (Bio-Rad Laboratories, Italy).
Uncropped images of most relevant immunoblots are provided in Supplementary
Fig. 12. Images derived from western blot were analyzed with ImageJ (National
Institute of Health, Bethesda, MD, USA) software. All samples were normalized for
protein loading by using Vinculin, GAPDH, Actin, or H3 (chosen as housekeeping
proteins). Recorded value was obtained from the ratio between arbitrary units
derived by the protein band and the respective housekeeping protein. All primary
antibodies used in the Western blot procedure are listed in Supplementary Table 4.
Morphological analysis. Immunostaining of cultured cells were carried out as
described previously17. Formaldehyde fixed cells were incubated with appropriate
antibodies and DAPI was used for nuclear staining. The samples were examined
with a fluorescence microscope (Carl Zeiss, Italy). Pictures of staining were
obtained using an AxioCam (Carl Zeiss Vision, Italy). Antibodies are listed in
Supplementary Table 4.
In vivo morphological evaluation was performed on OCT frozen TA muscles.
Transverse, 10-μm-thick sections were cut by a cryostat and collected on Superfrost
Plus slides (BioOptica). For each TA muscle (n= 3 per experimental group), a
minimum of 20 sections were processed for hematoxylin–eosin (H&E) staining,
dehydrated and mounted with Eukitt (Kindler GmbH & Co., Germany). For
immunofluorescence analysis of TA muscles, 10-μm frozen sections were blocked
with 10% Normal Goat Serum (NGS, Vector Laboratories) in PBS with 2.5%
Triton-X 100, and then incubated overnight at 4 °C with anti-p-AMPK (1:50,
anti-p-AMPK (Thr172)) and anti-p-FoxO3 (1:20, anti-p-FoxO3(Ser413)). Negative
controls were performed omitting the primary antibodies. Sections were
thoroughly rinsed with PBS, then incubated for 1 h at room temperature with PBS
containing 5% NGS and Alexa488-conjugated goat anti-rabbit IgG (1:500,
Invitrogen Life Technologies, Carlsbad, CA, USA). Slides were mounted with
Fluoroshield mounting medium with DAPI (Sigma Aldrich, Italy). Muscle slices
were observed under a Leica CTR6000 microscope (Leica, Germany) equipped with
Leica DFC360 camera (immunofluorescence visualization) and Leica DFC480
(bright-field visualization). Images were captured using Leica Application Suite
System and files were converted in Adobe photoshop CS5 format.
Patients’ skeletal muscle samples. Muscle samples were collected from rectus
abdominis muscle of 15 cachectic tumor patients (3 males colorectal cancer,
3 females colorectal cancer, 5 male pancreatic cancer, and 4 females pancreatic
cancer patients) and 8 non-tumor patients (3 males and 5 females). All patients
underwent elective laparoscopic surgery, during which muscle biopsy was
performed. Muscle biopsies were snap frozen in liquid nitrogen immediately
after surgery.
For each patient, a small piece of frozen muscle biopsy was powdered and
lysed in a buffer containing 50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2,
1 mM DTT, 10% glycerol, 1% SDS, 1% Triton X-100, 1X Roche Complete Protease
Inhibitor Cocktail, 1× Sigma-Aldrich Phosphatase Inhibitor Cocktail 1 and 3.
Then, samples were immunoblotted and visualized with SuperSignal West Pico
Chemiluminescent substrate (Pierce). Blots were stripped using Restore Western
Blotting Stripping Buffer (Pierce) according to the manufacturer’s instructions and
were reprobed if necessary.
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All enrolled subjects were volunteers who signed an informed consent to
participate in the study that took place at the Department of Surgery, Oncology and
Gastroenterology, 3rd Surgical Clinic, University of Padua. Study protocol
(Protocol 3674/AO/15) was approved by Ethical Committee for Clinical Research
in the district Padova (CESC).
Sample acquisition and preparation, data handling and encryption were
performed according to the 1996 Declaration of Helsinki.
Statistical analysis. Data obtained from functional, morphological, western blot,
and mRNA analysis are expressed as means± SD (standard deviation), whereas
data obtained from ChIP experiments are represented as means ± SEM (standard
error of the mean). When we compared two experimental groups, we used
unpaired Student’s t-test and when we compared three or more experimental
groups, we used one-way analysis of variance (ANOVA) followed by the Tukey’s
post hoc test. Values of p < 0.05 were considered to indicate a significant difference.
Statistical analysis was performed using GRAPHPAD INSTAT3 (GraphPad, La
Jolla, CA, USA) for Windows.
Data availability. The BRD4 ChIP-seq data have been deposited in the GEO
database under the accession code GSE104155. The authors declare that all the
other data supporting the findings of this study are available within the article and
its Supplementary Information files and from the corresponding author, upon
reasonable request.
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Supplementary Fig.1 pH3Ser10 phosphorylation is not affected by JQ1 treatment in C26 tumors 
p-H3 (Ser10) levels were assessed in C26 tumors by Western blot. 4 animals were used for each experimental group. Data represent 
means±SD. Statistical analysis was performed by using one-way ANOVA followed by Tukey’s post-hoc test. 
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Supplementary Fig.2. Changes in body weights in JQ1-treated mice, in survival experiments 
Body weights chart of control and JQ1-treated animals presented in Fig. 2C. Animals per group: n=7. Statistical analysis was 
performed by using one-way ANOVA. Data represent means±SEM. ****p<0.0001. 
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Supplementary Fig.3. Impact of JQ1 treatment on plasma cholesterol and target tissues  
(a-c) total, LDL- and HDL-cholesterol levels were measured in plasma samples of control, and C26 tumor-bearing mice treated with 
vehicle, (-)-JQ1 and (+)-JQ1. 5 animals were used for each experimental condition. Statistical analysis was performed by using one-
way ANOVA. Data represent means±SD. *p<0.05; ***p<0.001. “a” indicates statistical significance compared to Control; “b” 
indicates statistical significance compared to C26+vehicle; “c” indicates statistical significance compared to C26(-)-JQ1 20mg/kg/day; 
“d” indicates statistical significance compared to C26(-)-JQ1 50mg/kg/day. 
(d,e) Weight of heart and testis was determined 12 days after C26 cell implantation in C26 tumor-bearing mice treated with vehicle, (-
)-JQ1 and (+)-JQ1 (20 and 50 mg/kg/day). Animals per group: n=10. Data represent means±SD. Statistical analysis was performed by 
using one-way ANOVA followed by Tukey’s post-hoc test. **p<0.01; ***p<0.001. “b” indicates statistical significance compared to 
C26+vehicle; “c” indicates statistical significance compared to C26(-)-JQ1 20mg/kg/day; “d” indicates statistical significance 
compared to C26(-)-JQ1 50mg/kg/day. 
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Supplementary Fig.4. JQ1 administration prevents myofibers size reduction 
(a) histogram of fiber cross-sectional area (CSA) distribution of TA muscles from control, C26+vehicle, and C26(+)-JQ1. 
(b) average fiber CSA (average values ± 95% CI), in TA muscles from control, C26+vehicle, and C26(+)-JQ1 animals. Statistical 
analysis was performed by using one-way ANOVA followed by Tukey’s post-hoc test.. ***p<0.001; “a” indicates statistical 
significance compared to Control; “b” indicates statistical significance compared to C26+veh. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
